Study protocol of the InterVitaminK trial: A Danish population-based randomised double-blinded placebo-controlled trial of the effects of vitamin K (menaquinone-7) supplementation on cardiovascular, metabolic and bone health

Freja Bach Kampmann, Sanne Marie Thysen, Camilla Friis Bryde Nielsen, Klaus Fuglsang Kofoed, Lars Køber, Michael Huy Cuong Pham, Allan Vaag, Niklas Rye Jørgensen, Janne Petersen, Rikke Kart Jacobsen, Line Lund Kårhus, Axel Diederichsen, Marie Frimodt-Møller, Allan Linneberg*

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

14 Downloads (Pure)

Abstract

Introduction Vitamin K has been suggested to have protective effects against progression of vascular calcification and development of cardiovascular disease (CVD). However, few well-powered randomised controlled trials have examined whether vitamin K prevents progression of vascular calcification in individuals from the general population. The aim of the InterVitaminK trial is to investigate the effects of vitamin K supplementation (menaquinone-7, MK-7) on cardiovascular, metabolic, respiratory and bone health in a general ageing population with detectable vascular calcification. Methods and analysis The InterVitaminK trial is a randomised, double-blinded, placebo-controlled, trial. A total of 450 men and women aged 52-82 years with detectable coronary artery calcification (CAC), but without manifest CVD, will be randomised (1:1) to receive daily MK-7 (333 μg/day) or placebo tablets for 3 years. Health examinations are scheduled at baseline, and after 1, 2 and 3 years of intervention. Health examinations include cardiac CT scans, measurements of arterial stiffness, blood pressure, lung function, physical function, muscle strength, anthropometric measures, questionnaires on general health and dietary intake, and blood and urine sampling. The primary outcome is progression of CAC from baseline to 3-year follow-up. The trial has 89% power to detect a between-group difference of at least 15%. Secondary outcomes are bone mineral density, pulmonary function and biomarkers of insulin resistance. Ethics and dissemination Oral MK-7 supplementation is considered safe and has not been found to cause severe adverse events. The Ethical Committee of the Capital Region (H-21033114) approved the protocol. Written informed consent is obtained from all participants and the trial is conducted in accordance with the Declaration of Helsinki II. Both negative and positive findings will be reported. Trial registration number NCT05259046.

OriginalsprogEngelsk
Artikelnummere071885
TidsskriftBMJ Open
Vol/bind13
Udgave nummer5
Antal sider8
ISSN2044-6055
DOI
StatusUdgivet - 2023

Bibliografisk note

Publisher Copyright:
© 2023 BMJ Publishing Group. All rights reserved.

Citationsformater